Evidence map›Paper›PMID 41878892›Full record

ReviewCPT: pharmacometrics & systems pharmacology2026

Integration of Machine Learning With PBPK and QSAR Modeling Approaches to Facilitate Drug Discovery and Development.

Xinyue Chen, Zhoumeng Lin

Abstract readReview
In one paragraph

Review in CPT: pharmacometrics & systems pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Xinyue ChenDepartment of Environmental and Global Health, College of Public Health and Health Professions, University of Florida, Gainesville, Florida, USA.ORCID https://orcid.org/0009-0008-5916-5375
Zhoumeng LinDepartment of Environmental and Global Health, College of Public Health and Health Professions, University of Florida, Gainesville, Florida, USA.ORCID https://orcid.org/0000-0002-8731-8366

Funding

Development of a web-based predictive model of nanoparticle delivery to tumors by integrating physiologically-based pharmacokinetic modeling with artificial intelligenceR01EB031022 · NIBIB · UNIVERSITY OF FLORIDA · PI Zhoumeng Lin · 2021 to 2026
$2.2M
NIBIB NIH HHS R01 EB031022
6 · The paper itself

Abstract

This review examines the application of machine learning (ML) in physiologically based pharmacokinetic (PBPK) modeling through improved prediction of input parameters, particularly via quantitative structure-activity relationship (QSAR) models, for absorption, distribution, metabolism, and excretion (ADME) properties across drug development phases. Traditional PBPK models, while mechanistically sound, face limitations in applicability domain when compound-specific physicochemical and biochemical parameters (e.g., partition coefficients, metabolic clearance rates, plasma protein binding) cannot be reliably determined or estimated for novel chemicals. ML-enhanced QSAR models address these input parameter limitations by predicting required parameters directly from chemical structure, thereby extending PBPK applicability to diverse chemical space without altering the mechanistic model framework itself. Recent advances in ML-powered QSAR methodology generate higher-quality predictions of partition coefficients, clearance rates, and binding parameters. When these ML-predicted parameters are integrated as inputs into conventional PBPK frameworks, the resulting simulations often demonstrate significantly improved predictive accuracy compared to PBPK models using conventional regression-based QSAR inputs. This workflow-wherein ML enhances QSAR prediction quality, which subsequently improves PBPK simulation reliability through better input parameters-facilitates critical drug discovery and development decisions, from early candidate selection to clinical translation and safety assessment, potentially reducing pharmacokinetic-related drug candidate failures. However, challenges remain, including limited chemical diversity in QSAR training data sets, model interpretability concerns, and evolving regulatory considerations for ML-derived parameters in PBPK submissions. Future developments point toward seamless integration of ML-enhanced QSAR predictions as validated inputs for mechanistic PBPK models through standardized validation approaches and collaboration among academia, industry, and regulatory bodies.

Indexed as

Drug DevelopmentDrug DiscoveryMachine LearningModels, BiologicalQuantitative Structure-Activity RelationshipComputer SimulationHumansPharmaceutical PreparationsPharmacokineticsPredictive Learning ModelsPharmaceutical Preparationsdrug discovery and developmentmachine learningnanomedicinephysiologically based pharmacokinetic modelquantitative structure–activity relationship model

Identifiers

PMID41878892
PMCPMC13140458

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.